Evidence map›Paper›PMID 39641447›Full record

SynthesisImmunotherapy2024

Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.

Sze Wah Samuel Chan, Zainab Ali Amer Al Maqrashi, Jack Young, Do-Hoon Kim, Gregory Pond, Brandon M Meyers, Adi Kartolo

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sze Wah Samuel ChanDepartment of Oncology, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-9167-9431
Zainab Ali Amer Al MaqrashiDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Jack YoungDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Do-Hoon KimDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Gregory PondDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Brandon M MeyersDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Adi KartoloDepartment of Oncology, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and squamous cell carcinoma (HNSCC) in the locally advanced setting is challenging to treat and remains an area of significant morbidity and mortality. For patients who are cisplatin-ineligible and considered unresectable, there is no clear standard of care including the choice of radiosensitizer.

methodsOVID Medline, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched. Randomized clinical trials (RCTs) of cisplatin-ineligible unresectable HNSCC patients who were randomized to an immune checkpoint inhibitor concurrent with radiation compared to a control arm were included. Data was pooled and assessed using a random-effects model for the meta-analysis.

resultsThree eligible RCTs were identified and analyzed which comprised 594 patients whose median age ranged from 65-72 years. There was no difference in overall survival (pooled HR 1.02, 95% CI 0.76-1.37, CONCLUSIONS AND RELEVANCE: Immune-checkpoint inhibitors are not superior to cetuximab when used with definitive radiation in HNSCC. Further study is warranted, given its potential signal for non-inferior survival with less toxicity profile trends.

Indexed as

ChemoradiotherapyHead and Neck NeoplasmsImmune Checkpoint InhibitorsImmunotherapySquamous Cell Carcinoma of Head and NeckCisplatinHumansRandomized Controlled Trials as TopicCisplatinImmune Checkpoint Inhibitorschemoradiationcisplatin-ineligiblehead and neck squamous cell carcinomaImmune-checkpoint inhibitorsmeta-analysis

Identifiers

PMID39641447
PMCPMC11758945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.